Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

37.60
-0.9300-2.41%
Post-market: 37.38-0.2249-0.60%19:51 EDT
Volume:1.78M
Turnover:67.11M
Market Cap:4.00B
PE:45.85
High:38.44
Open:38.09
Low:37.15
Close:38.53
52wk High:117.33
52wk Low:28.66
Shares:106.37M
Float Shares:86.88M
Volume Ratio:0.43
T/O Rate:2.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.8200
EPS(LYR):0.8200
ROE:15.01%
ROA:3.34%
PB:6.17
PE(LYR):45.85

Loading ...

Corcept Therapeutics Inc : Piper Sandler Cuts Target Price to $73 From $121

THOMSON REUTERS
·
Feb 25

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 25

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

TIPRANKS
·
Feb 25

Corcept Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $60 From $67

THOMSON REUTERS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Investors File Securities Fraud Class Action Against Corcept Therapeutics

Reuters
·
Feb 25

Corcept Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 25

Stock Track | Corcept Therapeutics Plunges 5.43% After-Hours on Q4 Earnings and Revenue Misses

Stock Track
·
Feb 25

Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook

TIPRANKS
·
Feb 25

Corcept Therapeutics misses Q4 revenue expectations, net income drops 21%

Reuters
·
Feb 25

Corcept Q4 product revenue hits USD 202.1 million +37% tablets sold

Reuters
·
Feb 25

Corcept Therapeutics Q4 EPS $0.20 Misses $0.27 Estimate, Sales $202.125M Miss $254.936M Estimate

Benzinga
·
Feb 25

BRIEF-Corcept Therapeutics Q4 EPS USD 0.2

Reuters
·
Feb 25

Corcept Therapeutics Outlook FY Revenue USD 900-1,000 Million

THOMSON REUTERS
·
Feb 25

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

THOMSON REUTERS
·
Feb 25

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 24

Corcept faces securities class action lawsuit over relacorilant NDA claims

Reuters
·
Feb 24

Hagens Berman Files Securities Class Action Against Corcept Therapeutics

Reuters
·
Feb 24

Corcept Investors File Securities Class Action Over Relacorilant NDA Disclosures

Reuters
·
Feb 21

Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 20